Education
About Us
Working with TipRanks
Follow Us
Biocardia (BCDA)
:BCDA
BCDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $3.20
Previous CloseN/A
Volume12.78K
Average Volume (3M)1.07M
Market Cap
$14.43M
Enterprise Value$9.63M
Total Cash (Recent Filing)$980.00K
Total Debt (Recent Filing)$745.00K
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 05, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding10,608,734
10 Day Avg. Volume887,425
30 Day Avg. Volume1,065,735
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue166.06
Enterprise Value/Gross Profit-22.35
Enterprise Value/Ebitda-1.11
Forecast
1Y Price Target
$25.00Price Target Upside1738.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBiocardia announced financial results with an EPS better than the analyst's estimate, indicating better-than-expected financial performance.
Financial StabilityThe company has enough cash to fund ongoing operations through the first quarter of 2025, providing financial stability in the near term.
New ProductMorph DNA Introducer now commercially available, providing new revenue stream.
Bears Say
Clinical TrialDSMB determined that the study would not meet the primary Finkelstein Schoenfeld composite endpoint and recommended to pause enrollment.
Regulatory ChallengesPMDA willing to review CardiAMP HF data ahead of submission for approval in Japan.
BioCardia News
BCDA FAQ
What was Biocardia’s price range in the past 12 months?
Biocardia lowest stock price was $1.00 and its highest was $3.20 in the past 12 months.
What is Biocardia’s market cap?
Biocardia’s market cap is $14.43M.
When is Biocardia’s upcoming earnings report date?
Biocardia’s upcoming earnings report date is Nov 05, 2025 which is in 31 days.
How were Biocardia’s earnings last quarter?
Biocardia released its earnings results on Aug 11, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.5 by $0.1.
Is Biocardia overvalued?
According to Wall Street analysts Biocardia’s price is currently Undervalued.
Does Biocardia pay dividends?
Biocardia does not currently pay dividends.
What is Biocardia’s EPS estimate?
Biocardia’s EPS estimate is -0.23.
How many shares outstanding does Biocardia have?
Biocardia has 10,608,734 shares outstanding.
What happened to Biocardia’s price movement after its last earnings report?
Biocardia reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.5. Following the earnings report the stock price went down -6.145%.
Which hedge fund is a major shareholder of Biocardia?
Currently, no hedge funds are holding shares in BCDA
Company Description
Biocardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
BCDA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and regulatory pathways, particularly in Japan, with promising partnership discussions. However, increased R&D expenses, a rise in net loss, and low cash reserves present challenges. The sentiment is cautiously optimistic with a focus on regulatory approvals and strategic partnerships.View all BCDA earnings summariesBCDA Stock 12 Month Forecast
Average Price Target
$25.00
▲(1738.24% Upside)
Technical Analysis
AlphaTON Capital
―
ETHZilla Corporation
―
BioRestorative Therapies
―
Lyra Therapeutics
―
Bolt Biotherapeutics
―
Ownership Overview
18.67% Insiders
0.77% Mutual Funds
2.26% Other Institutional Investors
78.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---